-

Invenra Unveils Rapid Bispecific Antibody Discovery Services – 4 Months from Start to Finish

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined service can identify bispecific antibody lead panel candidates in as little as four months.

With these accelerated services, Invenra continues to build on its reputation for groundbreaking, client-focused discovery models. Recognizing the critical need for faster timelines in preclinical antibody discovery, the service is designed to meet the growing demand for expedited preclinical discovery on time-sensitive projects.

“Our team is committed to accelerating bispecific antibody discovery without compromising quality or precision,” said Roland Green, CEO. “This new approach harnesses our advanced technologies and refined workflows, empowering both established and early-stage biopharmaceutical companies to meet ambitious timelines and bring innovative treatments to patients faster.”

The new rapid discovery service complements Invenra’s established role as a strategic partner in antibody discovery and development. For those seeking a comprehensive partnered approach, Invenra continues to offer tailored support across all discovery stages, including custom antigen design, cell line generation, assay development, and in-depth biological analysis - each customized to meet the unique objectives of its partner.

About Invenra

Invenra Inc. provides innovative pharmaceutical discovery and development services, specializing in antibody discovery and development for a range of therapeutic applications. For more information, please visit invenra.com.

Contacts

Bryan Glaser
Senior Vice President, Business Development
Invenra Inc.
Phone: 608-441-8319
Email: bglaser@invenra.com

Industry:

Invenra Inc.

Release Versions
English

Contacts

Bryan Glaser
Senior Vice President, Business Development
Invenra Inc.
Phone: 608-441-8319
Email: bglaser@invenra.com

More News From Invenra Inc.

Invenra and Orion Announce Discovery Service and Commercial License Agreement to Develop Innovative Bispecific Antibody Cancer Therapeutics

MADISON, Wis.--(BUSINESS WIRE)--Orion Corporation (“Orion”), a globally operating pharmaceutical company, and Invenra Inc., an innovative biotechnology company with proprietary technologies for discovering novel therapeutics, today announced that they have entered into a research collaboration to discover bispecific antibodies using Invenra’s B-Body® platform. Under the terms of the agreements, Invenra will leverage its B-Body® bispecific antibody platform from monoclonal antibody discovery to...

Invenra Welcomes Three Industry Leaders to Its Board of Directors

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the addition of three distinguished professionals to its Board of Directors: Saira Ramasastry, Heather Preston, MD, and William Hinshaw. Together, these leaders bring decades of expertise in life sciences, encompassing clinical development, biotherapeutic commercialization, and strategic growth within the biotechnology industry. Saira Ramasastry has over 25 years of experience in the life sciences, successfully building compani...

Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc. is pleased to announce that its innovative bispecific antibody, INV724, developed for the treatment of neuroblastoma, has been awarded both Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations by the U.S. Food and Drug Administration (FDA). These designations provide strategic advantages, including accelerated development, cost reductions, and financial incentives, further driving the advancement of groundbreaking therapies for rare pedia...
Back to Newsroom